Bifogade filer
Press release
Kurs
-0,44%
Kalender
| Est. tid* | ||
| 2028-01-28 | N/A | Bokslutskommuniké 2027 |
| 2027-10-25 | 07:30 | Kvartalsrapport 2027-Q3 |
| 2027-07-27 | 07:30 | Kvartalsrapport 2027-Q2 |
| 2027-04-23 | 07:30 | Kvartalsrapport 2027-Q1 |
| 2027-01-29 | N/A | Bokslutskommuniké 2026 |
| 2026-10-30 | 07:30 | Kvartalsrapport 2026-Q3 |
| 2026-07-30 | 07:30 | Kvartalsrapport 2026-Q2 |
| 2026-05-05 | N/A | X-dag ordinarie utdelning SAN 4.12 EUR |
| 2026-04-29 | N/A | Extra Bolagsstämma |
| 2026-04-29 | N/A | Årsstämma |
| 2026-04-23 | 07:30 | Kvartalsrapport 2026-Q1 |
| 2026-01-29 | - | Bokslutskommuniké 2025 |
| 2025-10-24 | - | Kvartalsrapport 2025-Q3 |
| 2025-07-31 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-12 | - | X-dag ordinarie utdelning SAN 3.92 EUR |
| 2025-04-30 | - | Extra Bolagsstämma |
| 2025-04-30 | - | Årsstämma |
| 2025-04-24 | - | Kvartalsrapport 2025-Q1 |
| 2025-01-30 | - | Bokslutskommuniké 2024 |
| 2024-10-25 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-25 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-13 | - | X-dag ordinarie utdelning SAN 3.76 EUR |
| 2024-04-30 | - | Extra Bolagsstämma |
| 2024-04-30 | - | Årsstämma |
| 2024-04-25 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-01 | - | Bokslutskommuniké 2023 |
| 2023-10-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-28 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-30 | - | X-dag ordinarie utdelning SAN 3.56 EUR |
| 2023-05-25 | - | Extra Bolagsstämma |
| 2023-05-25 | - | Årsstämma |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-03 | - | Bokslutskommuniké 2022 |
| 2022-10-28 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-28 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-06 | - | X-dag ordinarie utdelning SAN 3.33 EUR |
| 2022-05-03 | - | Årsstämma |
| 2022-05-03 | - | Extra Bolagsstämma |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-04 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-29 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-05 | - | X-dag ordinarie utdelning SAN 3.20 EUR |
| 2021-04-30 | - | Årsstämma |
| 2021-04-28 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-05 | - | Bokslutskommuniké 2020 |
| 2020-10-29 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-29 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-04 | - | X-dag ordinarie utdelning SAN 3.15 EUR |
| 2020-04-28 | - | Extra Bolagsstämma |
| 2020-04-28 | - | Årsstämma |
| 2020-04-24 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-06 | - | Bokslutskommuniké 2019 |
| 2019-10-31 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-26 | - | Kvartalsrapport 2019-Q1 |
Beskrivning
| Land | Frankrike |
|---|---|
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
Paris, February 17, 2026. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).
These documents are available on the company’s website:
https://www.sanofi.com/en/investors/reports-and-publications/financial-reports-and-regulated-information
In addition, the Form 20-F is available on the website of the SEC (www.sec.gov) and the “Document d’Enregistrement Universel” is available on the website of the AMF (www.amf-france.org). A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request.
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and creating compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Léo Le Bourhis | + 33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com
Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com
Thibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com